Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 plus standard chemotherapy and bevacizumab in first-line metastatic microsatellite-stable colorectal cancer
2025-523735-19-00Phase 3Authorised
- Sponsor
- Incyte
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in colorectal adenocarcinoma, microsatellite stable colorectal cancer and metastatic colorectal adenocarcinoma (mCRC) comparing INCA33890 + bevacizumab + chemotherapy with Placebo + bevacizumab + chemotherapy (2 arms). Primary endpoint: Progression-free survival. Planned start Jul 2026; status: authorised.
02
Drugs
INCA-33890
03
Conditions
colorectal adenocarcinomamicrosatellite stable colorectal cancermetastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-523735-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523735-19-00.